Epilepsy and pregnancy: good management reduces the risks

Area of Science:

• Neurology
• Obstetrics
• Pharmacology

Background:

• Anticonvulsant medications are frequently used by women of childbearing age.
• Certain anticonvulsants, particularly when used in combination, are associated with an increased risk of fetal malformations.
• Epilepsy management during pregnancy presents unique challenges for both mother and fetus.

Purpose of the Study:

• To review the risks associated with anticonvulsant use during pregnancy.
• To compare the potential teratogenicity of older versus newer anticonvulsant medications.
• To highlight the importance of preconception counseling for women with epilepsy.

Main Methods:

• Literature review of studies on anticonvulsant drug exposure and pregnancy outcomes.
• Analysis of risks including fetal malformation, seizure exacerbation, and adverse neonatal outcomes.
• Comparison of risks between different classes and combinations of anticonvulsants.

Main Results:

• The risk of fetal malformation is at least doubled for women using common anticonvulsants, especially in combination therapy.
• Newer anticonvulsants, gabapentin and lamotrigine, appear to pose a lower risk to the fetus.
• Approximately one-third of women with epilepsy experience increased seizure frequency during pregnancy, with rare instances of intrauterine fetal death.

Conclusions:

• Preconception medication review and optimization are essential for minimizing risks to the fetus.
• Careful management can lead to a high probability (over 90%) of a healthy baby for most women with epilepsy.
• The choice of anticonvulsant medication should be carefully considered in women planning pregnancy due to varying teratogenic potentials.